American Trust’s Amedisys AMED Stock Holding History

American Trust’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,306	Closed	-$225K	–	445
2022 Q1	$225K	Buy	+1,306	New	+$195K	0.02%	432

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

American Trust's AMED Position: Q2 2022 in Review

American Trust sold out of Amedisys (AMED) in Q2 2022, closing a stake of 1,306 shares — an estimated $225K sold.

American Trust first reported a position in AMED in Q1 2022 and held it in 1 quarter. The position peaked at $225K in Q1 2022. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

American Trust reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
American Trust sold 1,306 Amedisys shares in Q2 2022, an estimated $225K.
American Trust first reported a position in Amedisys in Q1 2022 and held it in 1 quarter.
American Trust's Amedisys position peaked at $225K in Q1 2022.
288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on American Trust's 13F filing for Q2 2022, filed 3 Oct 2022.